Seres Therapeutics (MCRB) Stock Analysis

What Seres Therapeutics does

Seres Therapeutics, Inc. is a pioneering microbiome therapeutics firm dedicated to engineering bacterial consortia that modulate host cells and tissues to combat various diseases. Their flagship therapeutic, SER-109, an oral microbiome treatment, has successfully concluded Phase III clinical trials for the management of Clostridioides difficile infection (CDI). The company's pipeline further encompasses SER-155, a synthetically cultured bacterial formulation currently undergoing Phase Ib evaluation. This candidate aims to mitigate the risk of gastrointestinal and bloodstream infections, alongside graft-versus-host disease, in vulnerable patients undergoing allogeneic hematopoietic stem cell or solid organ transplantation. Additionally, Seres Therapeutics is advancing SER-287 and SER-301, both in Phase Ib for ulcerative colitis, as well as SER-401, which targets metastatic melanoma, and SER-262, also directed at Clostridioides difficile infection. Seres maintains strategic alliances through licensing and collaboration agreements with entities such as Nestec Ltd. and Memorial Sloan Kettering Cancer Center. Established in 2010, the company previously operated as Seres Health, Inc. before adopting its current name in May 2015, and it maintains its principal offices in Cambridge, Massachusetts.

Key metrics

ETFs linked to MCRB

Broad-market and Healthcare sector ETFs an investor holding Seres Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how MCRB fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Seres Therapeutics?

Seres Therapeutics trades under the ticker MCRB on NASDAQ.

Which exchange is MCRB listed on?

MCRB is listed on NASDAQ.

What sector does Seres Therapeutics operate in?

Seres Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze MCRB in a portfolio?

PortView shows MCRB's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.